e-Drug3D

2179

VEPDEGESTRANT

INN
VEPDEGESTRANT

cas 2229711-68-4

CLASS

ANTINEOPLASTIC
HETEROBIFUNCTIONAL PROTEIN DEGRADER
TREATMENT OF METASTATIC BREAST CANCER
ESTROGEN RECEPTOR BINDING DOMAIN JOINED BY A LINKER TO AN E3 LIGASE BINDING DOMAIN

ROUTE (list)

ORAL

ATC code

PK parameters

Tmax 6 HOUR
VD 764 LITER
Cl 12 LITER / HOUR
PPB 99 PERCENT
t1/2 19 HOUR

Solubility

SLIGHTLY SOLUBLE IN WATER

Target

TARGET ESTROGEN RECEPTOR
E3 LIGASE

DrugCentral

Download SDF file

2,6-Piperidinedione, 3-[1,3-dihydro-1-oxo-5-[4-[[1-[4-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl]phenyl]-4-piperidinyl]methyl]-1-piperazinyl]-2H-isoindol-2-yl]-, (3S)-

Formula:
C45H49N5O4

Calculated chemical properties:

MW 723.89
NB_atoms 54
XLogP 6.05
PSA 104.017
NB_HD 2
NB_HA 9
fsp3 0.40
Lipinski(0=no;1=yes) 0

FDA
NDA 219835 (label) INN (VEPDEGESTRANT) VEPPANU (RIGEL PHARMS) APPROVAL= AP YEAR= 2026 NEWMOLECULARENTITY